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Abstract: Purpose: Reducing postprandial hyperglycemia has beneficial effects on diabetes-
related risk factors, but the magnitude of the reduction needed to achieve such an
effect is unknown.
To quantify the relationship of acute glucose and insulin postprandial responses with
longer-term effects on diabetes-related risk factors by performing a systematic review
and meta-analysis of dietary intervention studies.
Methods: We systematically searched EMBASE and MEDLINE. Dietary intervention
studies among any human population aiming to reduce postprandial glycaemia, with
actual measures of postprandial glucose (PPG) and/or insulin (PPI) as acute
exposures (incremental area under the curve, iAUC) as well as markers of glucose
metabolism (fasting glucose, HbA1c) and insulin sensitivity (fasting insulin, HOMA-IR)
after at least 4 weeks of diet intervention as outcomes, were included. Meta-analyses
were performed for the effects on acute exposures and on diabetes-related risk factors.
The relationship between changes in acute exposures and changes in risk factor
outcomes was estimated by meta-regression analyses.
Results: Out of the 13004 screened papers, 14 papers with 14 comparisons were
included in the quantitative analysis. The dietary interventions acutely reduced mean
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PPG (mean difference (MD), -0.27 mmol/l; 95% CI, -0.41 to -0.14) but not mean PPI
(MD, -7.47 pmol/l; 95% CI, -16.79 to 1.86). No significant overall effects on fasting
glucose and insulin. HbA1c was reduced by -0.20% (95%CI -0.35 to -0.05). Changes
in acute PPG were significantly associated with changes in fasting plasma glucose
(FPG) (per 10% change in PPG: β = 0.085 (95% CI, 0.003, 0.167), k=14), but not with
fasting insulin (β = 1.20 (95% CI, -0.32, 2.71), k=12). Changes in acute PPI were not
associated with changes in FPG (per 10% change in PPI: β = -0.017 (95% CI, -0.056,
0.022), k=11).
Conclusions: Only a limited number of postprandial glucose lowering dietary
intervention studies measured acute postprandial exposures to PPG/PPI during the
interventions. In this small heterogeneous set of studies, an association was found
between the magnitude of the acute postprandial responses and the change in fasting
glucose but no other outcomes. More studies are needed to quantify the relationship
between acute postprandial changes and long-term effects on risk factors.
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Brussels, 06 February 2020 
 
Subject: Article Submission 
 
To Whom It May Concern, 
 
We are hereby resubmitting our manuscript ‘Reducing postprandial glucose in dietary 
intervention studies and the magnitude of the effect on diabetes-related risk factors: a 
systematic review and meta-analysis’. We thank reviewers for their careful consideration of 
the paper and constructive comments. Below we provide point by point responses to 
reviewers’ comments. 
 
Reviewers' comments: 
 
Reviewer #1: The manuscript by Ruijgrok et al., titled "Reducing postprandial glucose in 
dietary intervention studies and the magnitude of the effect on diabetes-related risk factors: a 
systematic review and meta-analysis" aims to provide a comprehensive meta-analysis on 
the dietary intervention trials for glucose management.  While the topic is very current and 
relevant, there are concerns that need to be clarified: 
 
1.      The search was done until March 2018, which is >1 year ago. Please update.  
We have now updated the search until September 2019. This updated yielded 917 titles, of 
which 24 were screened full-text and 2 were included in the systematic review and meta-
analysis. This is now revised throughout the methods and the results of the paper.  
 
2.      This systematic review and meta analysis concerns the acute effect of dietary 
interventions on postprandial glycemia. There is certainly confusion on behalf of the reader 
as to the scope of this paper. The reader is under the impression that dietary interventions 
within a broad scope are being evaluated (ie title and abstract). In the introduction, the 
authors focus on the low GI/GL foods on postprandial glycemia. Moreover, the search terms 
are primarily capturing GI/GL as intervention material.  The authors end up with 2/13 
comparisons evaluating mulberry leaf extract (a dietary supplement) and remaining 
comparisons of GI/GL.  If the objective is to quantify postprandial effect of low vs high GI/GL 
interventions following continued exposure, please adjust the title and abstract objective to 
more clearly reflect the topic studied, and consider excluding mulberry extract studies. 
Otherwise, please open the search to all dietary interventions (and/or supplements) and 
revise the analysis to reflect the aim.   
The reviewer is correct that dietary interventions with a broad scope were evaluated. The 
search was designed to identify dietary interventions that aimed at reducing acute glycaemic 
exposures (as an inclusion criterion, and reflected as such in the search term) to investigate 
their longer term effects on glycaemic markers. This is the reason for having ‘glycaemic’ (not 
only glycaemic index (MESH)) in the search terms. This could be any diet, food or 
supplement that induced a reduction in acute glycaemic exposure, either by glycaemic 
index, load or glycaemic response. Indeed, most of the included studies, the interventions 
were characterized as low GI/GL, and two were mulberry extract studies. It should be noted 
that there was a wide variety in low GI/GL diets. The GI/GL interventions comprised the 
whole diet low GI (LGI) versus high GI (HGI) (6 comparisons), low GI breakfast (1 
comparison), type of rice (2 comparisons) and liquid carbohydrate-modified supplement (2 
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comparisons). To better emphasis the variation in diet types, this is now added in the results 
section as follows in the methods on page 5, line 107-108:  
‘involved any dietary intervention that aimed at reducing GI, GL, or postprandial glucose 
responses;’  
and in the results sections as follows on page 9, line 202-205:  
‘Two out of 14 comparisons aimed to reduce postprandial glucose via mulberry leaf extract 
supplementation [14,19] while the other comparisons were dietary interventions of whole diet 
low GI (LGI) versus high GI (HGI) (6 comparisons), low GI breakfast (1 comparison), 
carbohydrate-reduced high-protein diet (1 comparison), type of rice (2 comparisons) and 
liquid carbohydrate-modified supplement (2 comparisons).’. 
 
Other: 
3.      Line 102 - studies were included if individuals had pre-diabetes. Was this as defined by 
the individual studies or based on specific criteria/guidelines? 
Studies among any human population were eligible, therefore definitions for pre-diabetes 
were not relevant as inclusion criterion. Given the context of the topic it was explained in the 
paper that ‘any human population’ involved healthy individuals as well as (pre)-diabetes 
patients (type 1 and type 2 diabetes mellitus) as follows on page 5, line 107:  
‘studied any human population, including healthy individuals and individuals with 
prediabetes, type 1 and type 2 diabetes mellitus’.  
4.      Line 155 - Random effects method was used if number of comparisons was > 10 
however, in Supplementary Figure 4 (C) - there are 6 comparisons listed in the forest plot 
and random effects method was used. Should this be changed to fixed effects? 
Line 155 refers to the random effects meta-regression analyses, and not the forest plots in 
supplementary Figures which are regular meta-analyses. The Cochrane handbook (chapter 
9.6.4) was applied for conducting meta-regression analyses, which proposes to only 
consider meta-regression when there are more than 10 comparisons in a meta-analysis.  
5.      Line 168-170 - planned subgroup analyses for normal vs abnormal glucose 
metabolism was not conducted because < 10 comparisons; however based on results 
below, there are > 10 comparisons for many observations?  (i.e. Line 191- 194 - "The total 
number of comparisons retrieved from the included set of papers for the quantitative 
analyses was 13. For PPG, there were 13 comparisons with outcome FPG, 11 with fasting 
insulin, and 6 with HbA1c. For PPI, there were 10 comparisons with outcome FPG, 9 for 
fasting insulin, and 3 for HbA1c.") 
The reviewer is correct that for a number of outcomes there were more than 10 
comparisons. For these comparisons a meta-regression was conducted, while this was not 
performed for the outcomes were there were less than 10 comparisons. However, by 
creating subgroups of data (studies in normal versus abnormal glucose metabolism) the 
number of comparisons within one of the subgroups became smaller than 10 comparisons. 
Therefore meta-regression analyses stratified by subgroup could not be conducted because 
of the small number of studies.  
 
6.      Line 183 - Provide more detail on how papers were found manually ie: Were the 
references of included studies searched?  
The manually identified papers were identified in the process of developing the search string, 
or were from authors own files. References in included studies were not systematically 
searched. This is now explained on page 5, line 95-97.  
 
7.      Line 260-261 - "Other potential sources of heterogeneity were study quality, duration of 
the chronic intervention and compliance to diets." Consider exploring these sources of 
heterogeneity through post hoc analysis. Please include results of the subgroup analysis.  
We have considered exploring these sources of heterogeneity. However, as for the other 
subgroups analyses, creating subgroups for these sources of heterogeneity reduced the 
number of comparisons below 10, which was insufficient for a meta-regression analysis. 
 
 
 
 
 
 
 
8.      Supplementary Figure 3 (B) & Supplementary Figure 4 (B) - the scales of these forest 
plots makes it difficult to see the diamond displaying overall effect 
Review manager provides the scaling of the plot automatically and we cannot alter this. 
However, the overall estimate is displayed next to the diamond for the overall effect, which 
clarifies the effect size of the diamond.  
9.      Consider performing sensitivity analysis to determine whether one study exerted 
particular influence on the results 
The heterogeneity in our analyses was generally very low with an I-square statistic well 
below 50% for almost all comparisons. Therefore our results are not due to heterogeneity of 
the effects across studies and a sensitivity analysis to exclude specific studies will not yield 
different results.  
 
10.     Consider using GRADE to evaluate the certainty of the evidence 
 
Thank you for this suggestion. GRADE is a very relevant framework to evaluate evidence for 
making clinical practice recommendations. However, the research question of our study 
does not yet provide results that are at a phase to be applied in clinical practice. We have 
now phrased this as such in our discussion and conclusion without applying the GRADE 
system for this.  
 
Reviewer #2: MAJOR COMMENTS 
Abstract  
*       Line 37-41 - it is important to indicate the population as part of the inclusion criteria 
Agree, this is now added in the paper on page 2 line 38.  
 
*       Line - 45 - AUC is not defined. Also, the outcomes need to be specified in the abstract 
(i.e. was area under the curve, incremental area under the curve, or both extracted for data 
analysis). PPG/PPI are not outcomes. We use AUC/iAUC glucose/insulin to understand 
PPG/PPI, just like we use HbA1c to understand glycemic control. 
This is now added and changed in the abstract. 
 
Methods  
*       Search was conducted over 1 year ago. Please update.  
We have now updated the search until September 2019. This updated yielded 917 titles, of 
which 24 were screened full-text and 2 were included in the systematic review and meta-
analysis. This is now revised throughout the methods and the results of the paper.  
*       Line 135-136 - it is inappropriate to pool data with AUC and iAUC, as they occasionally 
produce different results depending on the baseline value.  
We admit that this is a confusing sentence, as this line refers to the data as extracted. We 
have now checked this again in all included studies and all data were used in iAUC. So, the 
exposure was calculated as a %change in iAUC. We have simplified the sentence now in the 
manuscript. 
 
*       Line 139-141 - What was extracted as the main endpoint(s) for the data analysis? Was 
it mean difference (MD)? Or relative changes? This needs to be specified in the methods.  
Agree, this should be clarified. We have added this to the methods section on page 7 line 
148 as follows: ‘The outcome was a mean difference between intervention and control’. 
 
Results  
*       Serious methodological limitation: some acute and chronic trials within a study were 
conducted in different populations (Asai et al., Kallio et al., McMillan-Price et al., Nakayama 
et al., Shimabukuro et al., 2013). Some may argue that this equivalent to a treatment type 
being studied by two different authors (i.e. same treatment (x), author 1 studies x in acute 
setting; author 2 studies x in long-term setting. If this is the case, there may be quite a few 
 
 
 
 
 
 
trial comparisons that may have been missed that could answer the main study question.  
o       For example, several comparisons may be extracted from the following meta-analyses: 
       Evans et al. 2017, Fructose replacement of glucose or sucrose in food or beverages 
lowers postprandial glucose and insulin without raising triglycerides: a systematic review and 
meta-analysis, AJCN 
       Evans et al. 2017, Chronic fructose substitution for glucose or sucrose in food or 
beverages has little effect on fasting blood glucose, insulin, or triglycerides: a systematic 
review and meta-analysis, AJCN  
We do not agree with the suggestion of the reviewer that studies of similar treatments by 
different authors (investigator groups, labs) could have been included in the present review. 
The differences between ‘authors’ will inevitably involve differences in meal composition 
(caused by sources and availability of foods, preparation methods), as well as study 
protocol, including laboratory measurements. We have extrapolated acute effects from 
different populations only in cases where authors themselves referred to the acute study and 
described this as the same intervention type. In addition, we checked the references kindly 
provided by the reviewer. The reason not to include these in de present study is that the 
acute and chronic exposures were not investigated by the same authors or in the same 
groups of individuals, which was an important part of the remit for this meta-analysis, as 
previously mentioned. In addition, we updated our systematic review until September 2019 
and this yielded 1 additional study on acute effects that was combined with an already 
identified study. We now included this pair of studies in our review and meta-analysis and 
updated this throughout the paper.  
 
*       The duration of the acute studies was different (i.e. 180 mins, 240 mins) among studies 
which could produce larger AUCs by nature of design (even if they are crossover studies). 
How were these adjusted for? This could also possibly add to the heterogeneity. Ratio of 
means could be a possible alternative.  
The reviewer is correct that duration of responses differed between studies. We have 
adjusted for this by using the difference in iAUC as a % of the control iAUC. One could argue 
that larger differences can potentially be seen with shorter measurement duration, as the 
largest potential reductions in postprandial response may be apparent in the early phase of 
the postprandial response. However, this is all speculative and probably dependent on the 
type of intervention. The ratio is an interesting concept and carefully considered the papers 
provided below. However, the ratio does not provide advantage over a percentage in ruling 
out the heterogeneity caused by different durations. Moreover, using a ratio complicates the 
interpretation of the results. We therefore did not use a ratio to present our results.  
 
o       Friedrich et al. 2008, The ratio of means method as an alternative to mean differences 
for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med 
Res Methodol.  
o       Friedrich et al. 2011, Ratio of means for analyzing continuous outcomes in meta-
analysis performed as well as mean difference methods. J Clin Epidemiol.  
 
MINOR COMMENTS  
Abstract  
*       Line 34 - "the relationship of acute glucose *and* insulin postprandial responses…" 
Done. 
*       Line 39 - postprandial glucose (PPG) *and/or* 
Done 
*       Line 46 - units for MD are not correct. Shouldn't they be mmol*min/L and pmol*min/L?  
The units are correct since the MD of postprandial responses was given as a AUC (unit 
mmol*h/L) corrected for time (divided by h), which implies that units are mmol/l and pmol/l. 
The time correction was needed for standardized analyses of MD in PPG. The interpretation 
of the MD is the difference in average PP level (averaged over time of the postprandial 
period). The reviewer is correct that this is confusing, we changed AUC in ‘mean PPG’, and 
 
 
 
 
 
 
explained this method in the data analysis section on page 7 line 165-166: ‘In these 
additional analyses, the postprandial exposures were expressed as mean postprandial 
levels, calculated as iAUC divided by time’. 
 
Introduction  
*       Line 60 - redundant sentence. How about, "Obesity and type 2 diabetes (T2D) are 
major global concerns"?  
Done 
*       Line 62-63 - "Postprandial *hyper*glycemia, *hyper*insulinemia, and *hyper*lipidemia, 
have been…"  
Done. 
*       Line 64 - "Moreover, *elevated fasting and postprandial glucose levels are* …"  
Done. 
*       Line 68-69 - glucose regulation, as measure by what?  
This phrasing was unclear and replaced by: ‘Indeed, in non-diabetic hyperglycaemia lifestyle 
treatment or medication to improve glycaemic control was associated with a reduced risk of 
future diabetes’ on page 3 line 72-73.  
 
*       Line 76 - "has *not* been *quantified*"   
Done. 
Methods  
*       For Supplementary file 1, create a table and include each search term(s) as a row to 
make it easier to read  
Done. 
*       Line 101 - "by two reviewers". Please indicate who they were.  
Done, this is now included on page 5 line 104-106.  
 
*       Line 102 - 103 - "individuals *with prediabetes, type 1 and type 2 diabetes mellitus*;…"  
Done 
*       Line 153 - Why 0.8? Why not 0.5? Please indicate rationale.  
We used a correlation of 0.8 to calculate the variance for cross-over studies. Based on 
previous studies, we assumed a correlation of 0.8 between two measurements within one 
subject. Since it is a correlation between measurements within one subject, 0.5 is probably 
too low.  
Results  
*       Line 195 - Table 1  
o       For column, "Effect measure" -->  
       please indicate AUC/iAUC glucose/insulin instead of PPG/PPI. PPG/PPI are not the 
outcomes. We use AUC/iAUC to understand PPG/PPI, just like we use HbA1c to understand 
glycemic control. 
Done. 
       For "insulin", please specify whether it is "fasting insulin" or "random insulin" 
Done. 
*       Line 210-211 - please specify direction of change as well 
The direction of the change is specified by the minus sign. 
 
*       Line 212 - again, absolute PPG is not an outcome. Please indicate whether the MD 
represents pooled AUC, iAUC, or both.  
Mean difference represents the mean postprandial glucose level (calculated ad iAUC/time). 
PPG was changed to ‘mean PPG level’.  
 
*       Line 212 - 217 - please specify correct units for MDs.  
mean PPI level, in mmol/l for glucose and pmol/l for insulin. This was added. 
Supplementary File  
 
 
 
 
 
 
 
*       Supp Figure 1 - please indicate what the red and green symbols mean in the figure 
legend. 
This is now added: ‘Red dot, high risk of bias. Green dot, low risk of bias’. 
Enclosed please find our manuscript entitled “Reducing postprandial glucose in dietary 
intervention studies and the magnitude of the effect on diabetes-related risk factors: a 
systematic review and meta-analysis” which we wish to submit for your consideration in 
the European Journal of Nutrition. 
 
Elevated glucose levels in the postprandial state are a key feature of impaired glucose 
tolerance and diabetes and are a risk marker for cardiovascular diseases. However, despite 
considerable literature supporting the potential health benefits of reducing postprandial 
glucose (PPG), and insulin (PPI) exposures, the size of a clinically relevant PPG and PPI 
reduction is currently unknown. We performed a systematic review and meta-analysis of 
dietary intervention studies to quantify the relationship of acute glucose or insulin 
postprandial responses with longer-term effects on diabetes-related risk factors. We 
searched EMBASE and MEDLINE for dietary intervention studies aiming to reduce 
postprandial glycaemia, with actual measures of PPG or PPI as acute exposures as well as 
markers of glucose metabolism and insulin sensitivity after at least 4 weeks of diet 
intervention as outcomes.  
 
Only a limited number of postprandial glucose lowering dietary intervention studies 
measured acute postprandial exposures to PPG/PPI during the interventions. The present 
meta-analyses include 12 publications and provide quantitative estimates of effects of 
dietary interventions on PPG and PPI responses. In this small heterogeneous set of 
studies, no associations were found between acute postprandial responses and changes in 
longer-term diabetes-related risk factors. As conclusion, we recommend that, to enable 
setting quantitative benchmarks for PPG/PPI reductions, future dietary intervention 
studies should consider measuring PPG/PPI exposure to study diets before 
embarking on a long-term dietary intervention. Similarly, investigators should move 
beyond the single acute meal study and to follow-these up with a chronic intervention, in 
order to establish the true effects on metabolic risk. 
 
We look forward to hearing from you soon. 
 
Best regards,  
 
Matthieu Flourakis (on behalf of all authors). 
ILSI Europe 
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ABSTRACT  31 
Purpose: Reducing postprandial hyperglycemia has beneficial effects on diabetes-related 32 
risk factors, but the magnitude of the reduction needed to achieve such an effect is unknown. 33 
To quantify the relationship of acute glucose and insulin postprandial responses with longer-34 
term effects on diabetes-related risk factors by performing a systematic review and meta-35 
analysis of dietary intervention studies. 36 
Methods: We systematically searched EMBASE and MEDLINE. Dietary intervention studies 37 
among any human population aiming to reduce postprandial glycaemia, with actual 38 
measures of postprandial glucose (PPG) and/or insulin (PPI) as acute exposures 39 
(incremental area under the curve, iAUC) as well as markers of glucose metabolism (fasting 40 
glucose, HbA1c) and insulin sensitivity (fasting insulin, HOMA-IR) after at least 4 weeks of 41 
diet intervention as outcomes, were included. Meta-analyses were performed for the effects 42 
on acute exposures and on diabetes-related risk factors. The relationship between changes 43 
in acute exposures and changes in risk factor outcomes was estimated by meta-regression 44 
analyses. 45 
Results: Out of the 13004 screened papers, 14 papers with 14 comparisons were included 46 
in the quantitative analysis. The dietary interventions acutely reduced mean PPG (mean 47 
difference (MD), -0.27 mmol/l; 95% CI, -0.41 to -0.14) but not mean PPI (MD, -7.47 pmol/l; 48 
95% CI, -16.79 to 1.86). No significant overall effects on fasting glucose and insulin. HbA1c 49 
was reduced by -0.20% (95%CI -0.35 to -0.05). Changes in acute PPG were significantly 50 
associated with changes in fasting plasma glucose (FPG) (per 10% change in PPG: β = 51 
0.085 (95% CI, 0.003, 0.167), k=14), but not with fasting insulin (β = 1.20 (95% CI, -0.32, 52 
2.71), k=12). Changes in acute PPI were not associated with changes in FPG (per 10% 53 
change in PPI: β = -0.017 (95% CI, -0.056, 0.022), k=11).  54 
Conclusions: Only a limited number of postprandial glucose lowering dietary intervention 55 
studies measured acute postprandial exposures to PPG/PPI during the interventions. In this 56 
small heterogeneous set of studies, an association was found between the magnitude of the 57 
acute postprandial responses and the change in fasting glucose but no other outcomes. 58 
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More studies are needed to quantify the relationship between acute postprandial changes 59 
and long-term effects on risk factors.  60 
 61 
Keywords: glucose, insulin, glycemic index, glycemic load, HbA1c 62 
 63 
INTRODUCTION 64 
Obesity and type 2 diabetes (T2D) are major global concerns. Recent estimates of T2D 65 
expect dramatic increases by 2035 to reach 471 million of cases globally [1]. Postprandial 66 
hyperglycemia, as well as the related phenomena of hyperinsulinemia and hyperlipemia, 67 
have been implicated in the etiology of chronic metabolic diseases such as T2D [2]. 68 
Moreover, elevated fasting and postprandial glucose levels are consistently associated with 69 
an increased risk of cardiovascular events, even in the non-diabetic range [3]. To prevent 70 
diabetes, an integrated approach is required which includes both dietary modification and 71 
regular physical activity [4-6]. Indeed, in non-diabetic hyperglycaemia lifestyle treatment or 72 
medication to improve glycaemic control was associated with a reduced risk of future 73 
diabetes [7].  74 
A number of papers have hypothesized the value of consuming low glycemic index foods to 75 
decrease the overall glycemic response of the diet for long-term benefit. Meta-analyses of 76 
the effect of low glycemic index (GI) diets indeed demonstrated beneficial effects on body 77 
weight in people with obesity and prevention of T2D and cardiovascular diseases [8-10].  78 
However, the magnitude of the reduction of postprandial glycemic response using dietary 79 
interventions such as low GI foods or meals, compared to high GI interventions in relation to 80 
longer-term established diabetes-related risk factors has not been quantified. At the moment, 81 
the majority of dietary studies investigate individual foods and their ability to reduce glucose 82 
levels over a period of a single meal only. It is therefore important to understand the 83 
relevance of these single meal studies by investigating the quantitative reductions in 84 
PPG/PPI needed acutely to induce relevant changes on established longer-term risk factors 85 
chronically, and disease prevention ultimately. Therefore, the aim of this work was to quantify 86 
4 
 
the relationship between acute glucose and insulin postprandial responses and their effects 87 
on diabetes-related risk factors over time by performing a systematic review and meta-88 
analysis of controlled postprandial glucose-lowering dietary intervention studies.  89 
5 
 
METHODS 90 
 91 
Data source and searches 92 
The bibliographic databases Elsevier Medical Database (EMBASE) and the US National 93 
Library of Medicine database (MEDLINE via the PubMed portal) were systematically 94 
searched for relevant papers until September 13, 2019. Relevant papers that were identified 95 
while developing the search string or based authors own files were manually included when 96 
needed. Search terms were defined by the research question, including terms for 97 
GI/glycemic load (GL) dietary interventions, postprandial responses, and study design. 98 
Indexed terms were used from MeSH in PubMed and from EMtree in EMBASE. Free-text 99 
terms were used in both databases as well. The full search strategies for both databases can 100 
be found in Supplementary file 1. The protocol and search strategies used were registered 101 
at PROSPERO prior to the study being executed (CRD42018093153). 102 
 103 
Study selection 104 
Titles and abstracts were screened in duplicate, independently by pairs of reviewers (MA, 105 
JWB, JMD, LE, CR, FS, SV, MDR) and differences were resolved by consensus. Full-text 106 
papers were screened independently by two reviewers (MA, JWB, LE, MDR, CR) for 107 
eligibility. Studies were included if they: (I) studied any human population, including healthy 108 
individuals and individuals with prediabetes, type 1 and type 2 diabetes mellitus; (II) involved 109 
any dietary intervention that aimed at reducing GI, GL, or postprandial glucose responses; 110 
(III) reported measures of postprandial glucose (PPG) or postprandial insulin (PPI) as acute 111 
exposures to study diets; (IV) reported measures of glycemic control and/or insulin sensitivity 112 
over time as outcomes. Studies were excluded if they: (I) had a study duration < 4 weeks; (II) 113 
were not written in the English language; (III) had no control group; (IV) had co-interventions; 114 
(V) had changes in glucose-lowering medication use during study; (VI) had no accessible 115 
full-text. If eligible full text papers did not report acute PPG and PPI response data, papers 116 
were checked for references to related papers that had previously published this data. 117 
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Multiple arms of the same study were included when these arms were independent (had 118 
different control groups) [11]. 119 
 120 
Data extraction 121 
Data extraction of the included studies was performed by one reviewer (CR) and was 122 
appraised (for a random subsample) by a second reviewer (MA). Information on study 123 
design, population, intervention diet, acute PPG and PPI exposures (levels per time point, 124 
AUC, incremental AUC (iAUC) and outcome measures (markers of glycemic control and 125 
insulin sensitivity) were extracted. In case of missing data on exposures and outcomes, 126 
authors were contacted to provide the required information. If authors did not respond and 127 
relevant information was available in figures (i.e. bars for AUC, and responses per time point 128 
from graphs), data were extracted from figures using the Microsoft Excel add-in tool TM 129 
Image-to-data (tushar-mehta.com). 130 
 131 
Quality assessment 132 
Two reviewers (CR and MA) independently assessed the methodological quality of full-text 133 
papers using the Cochrane Risk of Bias Tool [12]. Differences in scores were resolved by 134 
consensus. Potential risk of bias was assessed by scoring 7 different items (random 135 
sequence generation, allocation concealment, blinding of participants and personnel, blinding 136 
of outcome assessment, incomplete outcome data, selective outcome reporting, other 137 
sources of bias) with low, high or unclear risk of bias and is presented in Supplementary 138 
Figure 1. 139 
 140 
Data synthesis and analysis 141 
Outcome data were extracted if reported for at least five comparisons. The exposure and 142 
outcome measures glucose and insulin, with variance measure were transformed into SI 143 
units (mmol/l for glucose (=0.0555*mg/dl) and pmol/l for insulin (=6*microU/ml)).  144 
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In case postprandial responses were reported as data per time point (in table or as a figure), 145 
iAUC’s were calculated by the trapezoidal method as net iAUC [13]. Relative changes in 146 
exposures PPG and PPI were calculated as 147 
iAUCintervention −iAUCcontrol
iAUCcontrol
× 100%. 148 
The outcome was a mean difference between intervention and control. Baseline and post-149 
intervention means with standard deviations (SD) or standard error of the mean (SEM) for 150 
the intervention and control groups were extracted, transforming SD into SEM (SEM=SD/√N, 151 
where N = subject population). When actual P-values were reported, these were used to 152 
estimate the SEM [11]. In parallel studies, the absolute change in outcomes was calculated 153 
by subtracting the change from baseline in the control group from the change from baseline 154 
in the intervention group. In crossover studies, the post-intervention measure of the control 155 
group was subtracted from the post-intervention measure of the intervention group. The 156 
variance of the absolute changes in outcomes was calculated as (√𝑆𝐸𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛
2 +  𝑆𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2 ) 157 
for parallel studies and 158 
(√𝑆𝐸𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑒𝑛𝑑
2 +  𝑆𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑒𝑛𝑑
2 − 2𝑟 ∗ 𝑆𝐸𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑒𝑛𝑑 ∗  𝑆𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑒𝑛𝑑) for crossover 159 
studies, assuming a within-subject correlation coefficient of 0.8. 160 
 161 
Random effects meta-regression analyses were conducted (if number of comparisons k > 162 
10) to estimate the association between changes in the acute PPG/PPI exposures and 163 
changes in longer-term risk factor outcomes. As additional analyses, overall effects on the 164 
acute postprandial exposures and on the outcome variables were estimated by meta-165 
analyses and illustrated by forest plots. In these additional analyses, the postprandial 166 
exposures were expressed as mean postprandial levels, calculated as iAUC divided by time. 167 
The Q test (Chi2 statistic, P<0.05) was used to evaluate between-study heterogeneity in 168 
meta-analysis and the residual heterogeneity in meta-regression analysis. The I2 statistic was 169 
used for quantification of the degree of heterogeneity and is interpretable as the percentage 170 
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of the total association that may be due to heterogeneity between studies (I2 > 50% was 171 
considered a meaningful level of heterogeneity) in meta-analysis and as the residual 172 
heterogeneity in meta-regression analysis after correction for the changes in acute PPG/PPI 173 
exposures. The Pearson correlation coefficient between the change in PPG and the change 174 
in PPI was calculated. Bubble charts were created to visualize the relationship between the 175 
% relative change in PPG/PPI and the change in diabetes-related risk factors. Planned 176 
subgroup analyses stratified by normal versus abnormal glucose metabolism (non-diabetic 177 
hyperglycemia or diabetes) could not be conducted (because of k comparisons ≤ 10 per 178 
subgroup). Instead, for each comparison, normal versus abnormal glucose metabolism was 179 
marked by color in the bubble charts (abnormal glucose metabolism was defined on a study 180 
group level, as being either impaired fasting glucose and/or impaired glucose tolerance 181 
and/or HbA1c > 5.7 (%) and/or use of glucose-lowering medication). 182 
Meta-analysis was conducted in Review Manager (RevMan version 5.3. Copenhagen): The 183 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Meta-regression analysis was 184 
performed in R version 3.4.2 using the Metafor package. 185 
 186 
 187 
  188 
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RESULTS 189 
The search retrieved 13,004 papers and an additional 3 potentially relevant papers were 190 
found manually and added to the database for screening (Figure 1). After removal of 191 
duplicates, 6,964 papers were screened based on titles and abstracts; 146 full-text papers 192 
were finally assessed for eligibility. Main reasons for exclusion were: acute effects not 193 
reported (58 out of 128 excluded papers), not a PPG-lowering dietary intervention, and not a 194 
controlled trial. A total of 18 papers were eligible, of which 14 papers delivered all relevant 195 
data needed for quantitative analyses [14-25]. Three studies reported acute and chronic 196 
effects of the same dietary intervention in different papers [18,26,27] and [22,28,29]. One 197 
paper [21] reported data from two intervention and two control diets, thereby adding two 198 
independent comparisons. The total number of comparisons retrieved from the included set 199 
of papers for the quantitative analyses was 14. For PPG, there were 14 comparisons with 200 
outcome FPG, 12 with fasting insulin, and 7 with HbA1c. For PPI, there were 11 comparisons 201 
with outcome FPG, 10 for fasting insulin, and 4 for HbA1c. 202 
Table 1 summarizes the characteristics of the studies included in the quantitative analyses. 203 
Two out of 14 comparisons aimed to reduce postprandial glucose via mulberry leaf extract 204 
supplementation [14,19] while the other comparisons were dietary interventions of whole diet 205 
low GI (LGI) versus high GI (HGI) (6 comparisons), low GI breakfast (1 comparison), 206 
carbohydrate-reduced high-protein diet (1 comparison), type of rice (2 comparisons) and 207 
liquid carbohydrate-modified supplement (2 comparisons). At baseline, five comparisons 208 
(four studies) included individuals with normal glucose metabolism and nine comparisons 209 
included individuals with abnormal glucose metabolism. The study duration ranged from four 210 
weeks to three months. The intervention was applied to ≥ 3 main meals in nine comparisons, 211 
and to < 3 main meals in five comparisons. The duration of postprandial measurement 212 
ranged from 120 to 540 minutes, with a median and most frequent duration of 180 minutes. 213 
The majority of the studies scored a high risk of bias on blinding of participants and 214 
personnel (Supplementary Figure 1). All studies scored a low risk of bias on blinding of 215 
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outcome assessment and selective reporting. Randomization and allocation concealment 216 
scored most frequently an unclear risk of bias. 217 
The acute relative change in iAUC glucose ranged from -121% to 3.5%, with a median of -218 
27.1%. The acute relative change in iAUC insulin ranged from -36.8% to 33.2%, with a 219 
median of -29.2%. The correlation between the change in iAUC glucose and the change in 220 
iAUC insulin was 0.69 (P = 0.019), see Supplementary Figure 2.  221 
Overall, the dietary interventions acutely reduced absolute mean PPG levels (mean 222 
difference -0.27 mmol/l; 95% CI, -0.41 to -0.14; P <0.0001; Supplementary Figure 3A) but 223 
this effect was not significant for mean PPI level (mean difference -7.47 pmol/l; 95% CI, -224 
16.79 to 1.86; P = 0.12; Supplementary Figure 3B). 225 
No significant overall chronic effects were found for dietary intervention studies on fasting 226 
plasma glucose (mean difference 0.03 mmol/l; 95% CI, -0.27 to 0.33; P = 0.83) and fasting 227 
insulin (mean difference 3.10 pmol/l; 95% CI, -2.37 to 8.56; P = 0.27), but an overall 228 
reduction in HbA1c was observed (mean difference -0.20%; 95% CI, -0.35 to -0.05; P = 0.01) 229 
(Supplementary Figure 4 A-C). 230 
The relationships between % relative acute changes in PPG/PPI and changes in FPG, 231 
fasting insulin, and HbA1c are presented in Figure 2 and Supplementary Figure 5. Three out 232 
of these six relationships had sufficient comparisons/data (k > 10) to conduct meta-233 
regression analyses (Figure 2). Changes in acute PPG responses were associated with 234 
changes in FPG (per 10% change in PPG: β = 0.085; 95% CI, 0.003, 0.167; k=14), but not 235 
with fasting insulin (β = 1.196; 95% CI, -0.321, 2.714; k=12). Changes in acute PPI 236 
responses were not associated with changes in FPG (per 10% change in PPI: β = -0.017; 237 
95% CI, -0.056, 0.022; k=11). By visual inspection, no differences in results were observed 238 
between studies with individuals with normal glucose metabolism versus studies with 239 
individuals with abnormal glucose metabolism (Figure 2). Heterogeneity of all meta-analyses 240 
and meta-regression results was always below an I2 of 50% with the exception of the overall 241 
effects of the interventions on FPG (96%) and the association between acute PPG response 242 
and FPG (91.4%).  243 
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 244 
DISCUSSION 245 
This systematic review and meta-analysis of controlled dietary intervention studies aimed to 246 
investigate the size of the association between acute PPG and PPI responses and longer-247 
term effects on diabetes-related risk factors. The evidence to examine this association was 248 
found to be limited to a set of 13 heterogeneous studies reporting 14 comparisons. An 249 
association was found between the size of the reduction in acute PPG exposures to study 250 
diets and FPG, but not between PPG and fasting insulin and HbA1c. No associations were 251 
found between acute PPI exposures and any of the outcomes.  252 
A strength of this meta-analysis was the systematic approach to identify studies. Moreover, 253 
among included studies, the range in both PPG changes (-121% to +4%), and PPI changes 254 
(-37% to +33%) was substantial, which provided enough variation in exposures to potentially 255 
identify an association with outcomes. An important limitation was that our systematic review 256 
procedure yielded only a small number of studies that actually assessed PPG and PPI 257 
exposures to the diets under study. Most studies that aimed to reduce such exposures have 258 
designed the study diets based on published GI tables, or assumed effects on PPG, without 259 
quantification of actual PPG exposures, and were therefore not eligible for the present 260 
review. This perhaps identifies a limitation in the way nutritional research is currently 261 
undertaken. The small number of studies reduced study power and precluded analyses of 262 
effects on other outcomes (HbA1c). Another limitation of this meta-analysis is that the set of 263 
included studies were heterogeneous in study design and the number of studies did not allow 264 
for stratification by these sources of heterogeneity. Some major sources of potential 265 
heterogeneity were glucose metabolism status and the intensity of the intervention. Indeed, 266 
subjects with normal and abnormal glucose metabolism might respond differently to low GI 267 
interventions with a greater change in FPG reported previously in subjects with poor 268 
glycemic control [9] . Intensity of the intervention varied as some involved all meals (whole 269 
diet approach) and others one meal only, which hampers quantification of PPG exposures 270 
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during the day. Other potential sources of heterogeneity were study quality, duration of the 271 
chronic intervention and compliance to diets.  272 
In our selected set of studies, a significant reduction in HbA1c but no other longer-term risk 273 
factors (fasting glucose and insulin) following PPG-lowering dietary interventions of at least 4 274 
weeks was found. These findings seem to be somewhat at odds with previous GI/GL 275 
epidemiologic and some intervention studies. Indeed, several prospective cohort studies 276 
have shown an association between GI/GL and the risk of T2D [30-33]. In a meta-analysis of 277 
prospective cohort studies, Barclay et al. concluded on an independent effect of GI/GL on the 278 
risk of developing T2D [34]. However, due to their observational nature one cannot exclude 279 
the role of confounders (e.g. other dietary factors) in the observed association with T2D.  280 
As reviewed by Blaak et al., results from short-term GI/GL intervention on insulin sensitivity 281 
and/or secretion still remain inconclusive [2]. While 11 studies demonstrated a beneficial 282 
effect on insulin sensitivity or insulin secretion, 10 papers did not report any difference. 283 
Livesey et al. performed a systematic review and meta-analysis of intervention trials on GI 284 
and markers of health [9]. They concluded on a favorable effect of consumption of reduced 285 
glycemic response diets on reduction of FPG and glycated proteins. However, the effect of 286 
low GI interventions seems to vary according to the subjects’ glucose control status. Indeed, 287 
the improvement in fasting blood glucose and glycated proteins was reported to be greater in 288 
subjects with poor fasting glucose control (> 5 mmol/L). Also, weak evidence suggested a 289 
reduction in fasting insulin concentration, only in people with overweight or obesity with 290 
fasting insulin concentrations above 100 pmol/L. We did not have sufficient data to tease out 291 
differential effects between individuals with normal versus abnormal glucose metabolism, but 292 
the visual inspection did not indicate any differences between studies among individuals with 293 
normal versus abnormal glucose metabolism. The discrepancies with Livesey’s meta-294 
analysis may be partially explained by the studies included [9]. Indeed, we only included 295 
studies in which the effect on the acute reductions of postprandial glycemia was quantified, 296 
while this effect was not assessed in most of the 45 publications included in Livesey et al’s 297 
meta-analysis [9]. Despite the lack of overall effect on fasting glucose, the present study 298 
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revealed a relationship of PPG with fasting plasma glucose. Given the heterogeneity of the 299 
studies and the lack of overall effect on fasting glucose, these results should be interpreted 300 
with care. On the other hand, our data do provide some support for a relationship between 301 
the size of the postprandial glucose response and the size of the reduction in fasting glucose.  302 
Although there is abundant evidence that elevated blood glucose, concomitantly with 303 
elevated insulin concentration, leads to a transitory deleterious metabolic and hormonal state 304 
and oxidative stress, involving the liver, the pancreas, skeletal muscles, lipid metabolism 305 
interactions as well as incretins and inflammatory parameters, the exact role of PPG and the 306 
relevant magnitude of effect in this process remains unknown [2]. However, it has been 307 
postulated that glycemic variability may be a much better indicator for related metabolic 308 
effects [35]. Indeed, multiple cohort studies have shown that a high glycemic variability is 309 
associated with an increased risk of cardiovascular disease in people with T2D independent 310 
from mean plasma glucose or HbA1c [36-38].  311 
Daily exposures to glucose can currently be measured relatively non-invasively via 312 
Continuous Glucose Monitoring (CGM) systems. In the present dataset, only one of the 313 
included studies utilized this system [28]. In an observational study that used CGM, a 314 
positive relationship between PPG and HbA1c was found, both in healthy individuals and 315 
those with diabetes [39]. Further application of CGM in (dietary) intervention studies that aim 316 
to reduce glycemic exposure would provide better understanding of achieved reductions in 317 
overall PPG exposure and variability. This will enable the estimation of relevant PPG 318 
reductions as well as setting benchmarks for PPG exposure in future interventions.  319 
In conclusion, only a limited number of postprandial glucose lowering dietary intervention 320 
studies measure the actual reductions in acute PPG/PPI to the intervention which they then 321 
go on to administer chronically. In this small heterogeneous set of studies, an association 322 
was found between the magnitude of the acute postprandial responses and the change in 323 
fasting glucose but no other outcomes. To enable setting quantitative benchmarks for 324 
PPG/PPI reductions, future dietary intervention studies should consider measuring PPG/PPI 325 
14 
 
exposure to study diets before embarking on a long-term dietary intervention. Similarly, 326 
investigators should be encouraged to move beyond the single acute meal study and to 327 
follow-these up with a chronic intervention, in order to establish the true effects on metabolic 328 
risk.  329 
  330 
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Figure 1. PRISMA flow chart of study inclusion. 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
GI, glycemic index; GL, glycemic load. 
 
Figure 2. Bubble charts of the relationship between % relative change in PPG and absolute 
change in (a) FPG (b) fasting insulin. (c) The relationship between % relative change in PPI 
and absolute change in FPG. The size of the bubbles indicates the weight of each study 
(inverse variance). a per 10% change in PPG. b per 10% change in PPI. 
Random effects meta-regression analyses were conducted (if number of comparisons k > 
10) to estimate the association between changes in the acute PPG/PPI exposures and 
changes in longer-term risk factor outcomes. The I2 statistic was used for quantification of the 
degree of heterogeneity and is interpretable as the percentage of the total association that 
may be due to heterogeneity between studies (I2 > 50% was considered a meaningful level of 
heterogeneity) in meta-analysis and as the residual heterogeneity in meta-regression 
analysis after correction for the changes in acute PPG/PPI exposures. Bubble charts were 
created to visualize the relationship between the % relative change in PPG/PPI and the 
change in diabetes-related risk factors. For each comparison, normal versus abnormal 
glucose metabolism was marked by color in the bubble charts (abnormal glucose metabolism 
was defined on a study group level, as being either impaired fasting glucose and/or impaired 
glucose tolerance and/or HbA1c > 5.7 (%) and/or use of glucose-lowering medication). Meta-
regression analysis was performed in R version 3.4.2 using the Metafor package. 
FPG, fasting plasma glucose; PPG, postprandial glucose; PPI, postprandial insulin. 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
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Figure 2. Bubble charts of the relationship between % relative change in PPG and absolute change in 
(A) fasting plasma glucose (FPG); (B) fasting insulin; (C) The relationship between % relative change 
in PPI and absolute change in FPG. Blue dot: Studies among individuals with normal glucose 
metabolism. Red dot: studies among individuals with abnormal glucose metabolism. The bubble size 
reflects the weight of the study in the analysis (inverse variance). a per 10% change in PPG. b per 10% 
change in PPI. 
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Table 1. Characteristics of the included diet studies 
 
Author, 
Year, 
Country 
 Characteristics of 
participants 
Study 
design 
Duration Intervention Control Provision of 
meals / products 
Effect 
measure 
Asai et al., 
2011, Japan 
Acute test 2 F and 8 M subjects 
with abnormal glucose 
metabolism (50.0 ± 
10.6 years) BMI 24.3 
± 1.7 kg/m² 
Randomize
d crossover 
120 min Carbohydrate 
tolerance test – 200 
g boiled white rice 
with 2 g of dry 
seasoning (311 kcal, 
70 g CHO, 4.8 g 
protein, 1.3 g fat) 15 
min after ingestion 
of a mulberry leaf 
extract capsule (6 
mg DNJ). 
Carbohydrate 
tolerance test with 
placebo capsule. 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
22 F and 43 M 
subjects with abnormal 
glucose metabolism 
(53.6 ± 6.4 years) BMI 
24.6 ± 2.5 kg/m² 
Randomize
d parallel 
12 
weeks 
Diet – applied to 
three main meals 
Mulberry leaf 
extract (6 mg DNJ) 
capsules were 
ingested t.i.d. before 
meals. 
Diet – applied to 
three main meals 
Placebo capsules 
were ingested t.i.d. 
before meals. 
The mulberry leaf 
extract and 
placebo capsules 
were provided. 
FPG, 
fasting 
insulin, 
HbA1c 
Bouche et 
al., 2002, 
France 
Acute test 11 M subjects with 
normal glucose 
metabolism (mean 46 
± 9.9 years) BMI 28 ± 
3.3 kg/m² 
 240 min LGI breakfast 
(38%). The breakfast 
had the same LGI 
percent as the diet 
for the chronic 
period. 
HGI breakfast 
(75%). The breakfast 
had the same HGI 
percent as the diet for 
the chronic period. 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
Same as above Randomize
d crossover 
5 weeks Whole diet approach 
LGI diet: foods with 
a GI < 45%. 
Whole diet approach 
HGI diet: foods with 
a GI > 60%. 
Special cereals 
and LGI cookies 
were provided, 
otherwise 
participants were 
supplied with a 
FPG, 
fasting 
insulin, 
HOMA 
Table
list of 
recommended 
daily intake of 
commonly used 
foods and a 
substitution list 
allowing 
exchanges within 
food groups. 
Giacco et 
al., 2014, 
Italy 
Acute test 31 F and 23 M 
subjects with normal 
glucose metabolism 
(57.2 ± 8.3 years) BMI 
31.8 ± 5.6 kg/m² 
 120 min Lunch meal 
resembling the 
composition of the 
recommended diet 
before start of the 
intervention. 
Lunch meal 
resembling the 
composition of the 
recommended diet 
before start of the 
intervention. 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
Same as above Randomize
d parallel 
12 
weeks 
Diet – applied to 
three main meals 
Whole-grain cereal 
products diet. 
Diet – applied to 
three main meals 
Refined cereal 
products diet. 
Cereal products 
represented 60-
80% of the daily 
CHO intake; the 
remaining 20-
40% were 
provided by fruits 
and vegetables. 
Test products in 
both diets were 
provided. 
FPG, 
fasting 
insulin, 
HOMA-
IR 
Kabir et al., 
2002, 
France 
Acute test 13 M subjects with 
abnormal glucose 
metabolism (59 ± 7.2 
years) BMI 28 ± 3.6 
kg/m² 
 180 min LGI breakfast that 
was the same as 
during the 
intervention period 
HGI breakfast that 
was the same as 
during the 
intervention period 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
Same as above Randomize
d crossover 
4 weeks Diet – applied to one 
main meal 
LGI breakfast (GI 
40%) 
Diet – applied to one 
main meal 
HGI breakfast (GI 
64%) 
Treatment foods 
for breakfasts 
were provided 
during the study 
FPG, 
fasting 
insulin, 
HbA1c 
  
(20% of daily 
energy 
requirements). 
Patients were 
recommended to 
consume 55% 
CHO, 15% 
protein, 30% fat. 
Kallio et al. 
2007 and 
Kallio et al. 
2008, 
Finland 
Acute test 9 F and 10 M subjects 
with metabolic 
syndrome 
BMI 31.9 ± 0.7 kg/m² 
 180 min The test meal 
consisted of oat and 
wheat breads or rye 
breads, 40 g 
cucumber, and 3 dL 
of a no-calorie 
orange drink. 
The test meal 
consisted of rye 
breads, 40 g 
cucumber, and 3 dL 
of a no-calorie 
orange drink. 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
23 F and 24 M 
subjects with abnormal 
glucose metabolism 
(55.1 ± 6.4 years) BMI 
32.0 ± 2.8 kg/m² 
Randomize
d parallel 
12 
weeks 
Whole diet approach 
Oat-wheat potato 
diet 
 
Whole diet approach 
Rye-pasta diet 
Participants 
replaced their 
normal breads and 
baked products 
with the test 
breads provided 
during the study 
(>25% daily 
energy intake). 
Pasta and 
powdered mashed 
potatoes were 
provided. 
FPG, 
QUICKI 
Kim et al., 
2014, Korea 
Acute test 23 F and 15 M 
subjects with abnormal 
glucose metabolism 
(51.6 ± 7.5 years) BMI 
25.3 ± 3.2 kg/m²  
 120 min A high-CHO meal in 
the morning (76 g of 
white bread and 24 g 
strawberry jam, 407 
kcal, 80 g CHO, 8 g 
protein, 9.7 g fat) 
followed within 15 
A high-CHO meal in 
the morning (76 g of 
white bread and 24 g 
strawberry jam, 407 
kcal, 80 g CHO, 8 g 
protein, 9.7 g fat) 
followed within 15 
 iAUC 
glucose, 
iAUC 
insulin 
min by MLAE tablet 
(407 kcal, 80 g 
CHO, 8 g protein, 
9.7 g fat) 
min by placebo tablet 
Chronic 
intervention 
Same as above Randomize
d parallel 
4 weeks Diets – applied to 
three main meals 
Six tablets of 
standardized MLAE 
with each meal (18 
tablets per day: 5 g 
MLAE (3.6 mg/g of 
DNJ)). 
Diets – applied to 
three main meals 
Six placebo (lactose) 
tablets with each 
meal (18 placebo 
tablets per day). 
MLAE tablets or 
placebo tablets 
provided. 
FPG, 
fasting 
insulin 
Mayr et al., 
2016, 
Germany 
Acute test 20 F and 20 M 
subjects with abnormal 
glucose metabolism 
(83.0 ± 5.8 years) 
BMI 23.9 ± 4.0 kg/m2 
 240 min 200 ml carbohydrate 
modified oral 
nutritional 
supplement. 
200 ml standard oral 
nutritional 
supplement. 
 iAUC 
glucose,  
Chronic 
intervention 
Same as above Randomize
d parallel 
12 
weeks 
Intervention – 
applied two times 
daily 
- 2 x 200 ml/day, in 
between regular 
meals, diabetes-
specific 
carbohydrate 
modified oral 
nutritional 
supplement (ONS). 
Control – applied 
two times daily 
Standard oral 
nutritional 
supplement (ONS) 2 
x 200 ml/day in 
between regular 
meals. 
The study 
nutritional 
products (ONS) 
were provided to 
the subjects. 
FPG, 
fasting 
insulin, 
HbA1c, 
HOMA-
index 
McMillan-
Price et al., 
2006, 
Australia 
Acute test 11 F subjects (26.5 ± 
14.6 years) BMI 30.0 
± 14.3 kg/m² 
Randomize
d crossover 
180 min Mixed meals 
representative of 
each diet were fed 
over 10-hour period  
  iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
98 F and 31 M 
subjects with normal 
glucose metabolism 
Randomize
d parallel 
12 
weeks 
Diets – whole diet 
approach 
High CHO (55% 
Diets – whole diet 
approach 
High CHO (55% 
All key CHO and 
protein foods and 
some preprepared 
FPG, 
fasting 
insulin, 
(31.8 ± 8.7 years) BMI 
31.2 ± 4.6 kg/m² 
E)/HGI 
 
High protein (25% 
E)/HGI 
E)/LGI 
 
High protein (25% 
E)/LGI 
meals were 
provided. 
HOMA-
IR 
Nakayama 
et al. 2017 
and 
Terashima et 
al. 2017, 
Japan 
Acute test 
 
 
13 F and 17 M 
subjects with abnormal 
glucose metabolism 
(61.1 ± 12.5 years) 
BMI 26.3 ± 3.9 kg/m2 
 180 min Breakfast with GBR 
and side dishes 
(omelet, hamburger, 
white fish fillet, or 
salmon) 
Breakfast with WR 
and side dishes 
(omelet, hamburger, 
white fish fillet, or 
salmon) 
 iAUC 
glucose 
Chronic 
intervention 
4 F and 12 M subjects 
with abnormal glucose 
metabolism (64.0 ± 8.8 
years) BMI 25.7 ± 5.6 
kg/m2 
Randomize
d crossover 
8 weeks Diets – applied to 
two main meals 
Glutinous brown 
rice twice daily 
Diets – applied to 
two main meals 
White rice twice 
daily 
 FPG, 
HbA1c 
Nazare et 
al., 2010, 
France 
Acute test 19 F and 19 M 
subjects with normal 
glucose metabolism 
(38.3 ± 9.2 years) BMI 
27.3 ± 1.5 kg/m² 
 270 min Breakfast consisting 
of plain biscuits 
(LGI) with exactly 
the same 
composition as those 
ingested during the 
study. 
Breakfast consisting 
of flakes (HGI) with 
exactly the same 
composition as those 
ingested during the 
study. 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
Same as above Randomize
d parallel 
5 weeks Whole diet approach 
LGI (GI < 50%) 
starch diet 
 
Whole diet approach 
HGI (GI > 70%) 
starch diet 
 
Cereal breakfast 
products 
(extruded cereals 
for the HGI group 
and plain biscuits 
for the LGI 
group), and black 
bread for the LGI 
group were 
provided. A 
detailed list was 
given to the 
participants 
indicating the 
FPG, 
fasting 
insulin, 
HOMA-
IR, 
QUICKI 
starches they were 
allowed to eat and 
the prohibited 
ones. 
Samkani et 
al. 2018 and 
Skytte et al., 
2019, 
Denmark 
Acute test 
 
14 M and 2 F subjects 
with type 2 diabetes 
and treated with 
metformin only 
(median age 65 (43-
70)) BMI 30 ± 4.4 
kg/m² 
Randomize
d crossover 
450 min Carbohydrate-
reduced high protein 
(31%E carb, 29%E 
protein, 40%E fat) 
breakfast (t=0) and 
lunch (t=270) 
Isoenergetic 
conventional 
diabetes (54%E carb, 
16%E protein, 30%E 
fat) breakfast (t=0) 
and lunch (t=270) 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
28 M and F subjects 
with type 2 diabetes 
Randomize
d crossover 
6 weeks Carbohydrate-
reduced high protein 
diet (30%E carb, 
30%E protein, 40%E 
fat) 
Isoenergetic 
conventional 
diabetes diet (50%E 
carb, 17%E protein, 
33%E fat) 
Full diet (five 
daily meals) were 
provided 
FPG, 
fasting 
insulin, 
HbA1c 
Shimabukur
o et al., 
2013, Japan 
Acute test 6 M subjects with the 
metabolic syndrome 
(41 ± 5 years) BMI 
28.1 ± 4.3 kg/m² 
 240 min A meal (450 kcal) 
including BR of 
Japonica variety 
(200 kcal) 
A meal (450 kcal) 
including WR of 
Japonica variety (200 
kcal) 
 iAUC 
glucose, 
iAUC 
insulin 
Chronic 
intervention 
27 M subjects with 
abnormal glucose 
metabolism (Age: 
unknown) BMI 26.7 ± 
3.5 kg/m² 
Randomize
d crossover 
8 weeks Diets – applied to 
one main meal 
Brown rice of 
Japonica variety in a 
single daily meal 
Diets – applied to 
one main meal 
White rice of 
Japonica variety in a 
single daily meal 
Rice was 
provided during 
the study. 
FPG, 
fasting 
insulin, 
HbA1c, 
HOMA-
IR 
Stenvers et 
al., 2014, the 
Netherlands 
Acute test 10 F and 10 M 
subjects with abnormal 
glucose metabolism 
(60 ± 7 years) BMI 
30.7 ± 6.4  kg/m² 
 180 min Low-glycemic 
response liquid meal 
(mean of the first 4 
days of the 
intervention period) 
Dutch whole-food 
breakfast was 
consumed (mean of 
the first 4 days of the 
intervention period) 
 iAUC 
glucose 
Chronic 
intervention 
Same as above Randomize
d crossover 
3 months Diets – applied to 
one main meal 
Low-glycemic 
response liquid 
Diets – applied to 
one main meal 
Free-choice breakfast 
Participants were 
provided with 
sufficient 
amounts of the 
FPG, 
fasting 
insulin, 
HbA1c 
breakfast 
(isoenergetic amount 
of Glucerna SR) 
low-glycemic 
breakfast in the 
preferred taste. 
 
Abnormal glucose metabolism: impaired fasting glucose and/or impaired glucose tolerance and/or HbA1c > 5.7 (%) and/or use of glucose-lowering medication 
BR, brown rice; CHO, carbohydrate; DNJ, deoxynojirimycin; E, energy; F, females; FPG, fasting plasma glucose; GBR, glutinous brown rice; GI, glycemic 
index; HGI, high glycemic index; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; LGI, low glycemic index; M, males; MLAE, mulberry 
leaf aqueous extract; ONS, oral nutritional supplement; PPG, postprandial glucose; PPI, postprandial insulin; QUICKI, Quantitative Insulin Sensitivity Check 
Index; WR, white rice
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